BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 30072503)

  • 1. Evaluation of
    Tinkle CL; Duncan EC; Doubrovin M; Han Y; Li Y; Kim H; Broniscer A; Snyder SE; Merchant TE; Shulkin BL
    J Nucl Med; 2019 Mar; 60(3):312-319. PubMed ID: 30072503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of
    Zukotynski KA; Vajapeyam S; Fahey FH; Kocak M; Brown D; Ricci KI; Onar-Thomas A; Fouladi M; Poussaint TY
    J Nucl Med; 2017 Aug; 58(8):1264-1269. PubMed ID: 28360212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium.
    Zukotynski KA; Fahey FH; Kocak M; Alavi A; Wong TZ; Treves ST; Shulkin BL; Haas-Kogan DA; Geyer JR; Vajapeyam S; Boyett JM; Kun LE; Poussaint TY
    J Nucl Med; 2011 Feb; 52(2):188-95. PubMed ID: 21233173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying radiation therapy response using apparent diffusion coefficient (ADC) parametric mapping of pediatric diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium.
    Ceschin R; Kocak M; Vajapeyam S; Pollack IF; Onar-Thomas A; Dunkel IJ; Poussaint TY; Panigrahy A
    J Neurooncol; 2019 May; 143(1):79-86. PubMed ID: 30810873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium.
    Poussaint TY; Vajapeyam S; Ricci KI; Panigrahy A; Kocak M; Kun LE; Boyett JM; Pollack IF; Fouladi M
    Neuro Oncol; 2016 May; 18(5):725-34. PubMed ID: 26487690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Drug Imaging:
    Jansen MH; Veldhuijzen van Zanten SEM; van Vuurden DG; Huisman MC; Vugts DJ; Hoekstra OS; van Dongen GA; Kaspers GL
    J Nucl Med; 2017 May; 58(5):711-716. PubMed ID: 27765855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T2-weighted images are superior to other MR image types for the determination of diffuse intrinsic pontine glioma intratumoral heterogeneity.
    Harward S; Harrison Farber S; Malinzak M; Becher O; Thompson EM
    Childs Nerv Syst; 2018 Mar; 34(3):449-455. PubMed ID: 29151166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium.
    Vajapeyam S; Brown D; Billups C; Patay Z; Vezina G; Shiroishi MS; Law M; Baxter P; Onar-Thomas A; Fangusaro JR; Dunkel IJ; Poussaint TY
    AJNR Am J Neuroradiol; 2020 Apr; 41(4):718-724. PubMed ID: 32241771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.
    Jansen MH; Lagerweij T; Sewing AC; Vugts DJ; van Vuurden DG; Molthoff CF; Caretti V; Veringa SJ; Petersen N; Carcaboso AM; Noske DP; Vandertop WP; Wesseling P; van Dongen GA; Kaspers GJ; Hulleman E
    Mol Cancer Ther; 2016 Sep; 15(9):2166-74. PubMed ID: 27325687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models.
    Kossatz S; Carney B; Schweitzer M; Carlucci G; Miloushev VZ; Maachani UB; Rajappa P; Keshari KR; Pisapia D; Weber WA; Souweidane MM; Reiner T
    Cancer Res; 2017 Apr; 77(8):2112-2123. PubMed ID: 28108511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy.
    Hirata T; Kinoshita M; Tamari K; Seo Y; Suzuki O; Wakai N; Achiha T; Umehara T; Arita H; Kagawa N; Kanemura Y; Shimosegawa E; Hashimoto N; Hatazawa J; Kishima H; Teshima T; Ogawa K
    J Neurosurg; 2019 Sep; 131(3):676-686. PubMed ID: 30239314
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Lucas JT; Serrano N; Kim H; Li X; Snyder SE; Hwang S; Li Y; Hua CH; Broniscer A; Merchant TE; Shulkin BL
    J Neurooncol; 2017 Mar; 132(1):163-170. PubMed ID: 28078638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic Pontine gliomas during treatment: implications for current response assessment strategies.
    Löbel U; Hwang S; Edwards A; Li Y; Li X; Broniscer A; Patay Z
    Neuroradiology; 2016 Oct; 58(10):1027-1034. PubMed ID: 27438806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma.
    Heiss JD; Jamshidi A; Shah S; Martin S; Wolters PL; Argersinger DP; Warren KE; Lonser RR
    J Neurosurg Pediatr; 2018 Dec; 23(3):333-342. PubMed ID: 30544335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can multiparametric MRI and FDG-PET predict outcome in diffuse brainstem glioma? A report from a prospective phase-II study.
    Goda JS; Dutta D; Raut N; Juvekar SL; Purandare N; Rangarajan V; Arora B; Gupta T; Kurkure P; Jalali R
    Pediatr Neurosurg; 2013; 49(5):274-81. PubMed ID: 25277867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation of magnetic resonance images in diffuse intrinsic pontine glioma: a survey of pediatric neurosurgeons.
    Hankinson TC; Campagna EJ; Foreman NK; Handler MH
    J Neurosurg Pediatr; 2011 Jul; 8(1):97-102. PubMed ID: 21721895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.
    Chiba Y; Kinoshita M; Okita Y; Tsuboi A; Isohashi K; Kagawa N; Fujimoto Y; Oji Y; Oka Y; Shimosegawa E; Morita S; Hatazawa J; Sugiyama H; Hashimoto N; Yoshimine T
    J Neurosurg; 2012 Apr; 116(4):835-42. PubMed ID: 22242671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computation of reliable textural indices from multimodal brain MRI: suggestions based on a study of patients with diffuse intrinsic pontine glioma.
    Goya-Outi J; Orlhac F; Calmon R; Alentorn A; Nioche C; Philippe C; Puget S; Boddaert N; Buvat I; Grill J; Frouin V; Frouin F
    Phys Med Biol; 2018 May; 63(10):105003. PubMed ID: 29633962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
    Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
    Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.